Venetoclax-based combinations for acute myeloid leukemia: optimizing their use in Latin-America

• Autores: Gómez-De León, A, Demichelis-Gómez, R, Pinedo-Rodríguez, A, Enriquez-Vera, D, Flores-Jiménez, JA, Ceballos-López, AA, Rodríguez-Mejorada, M, Herrera Riojas, MA, Ovilla-Martínez, R, Báez-Islas, P, Cota-Rangel, X, Neme-Yunes, Y, Inclán-Alarcón, S, López-Flores, NJ, Colunga-Pedraza, PR, Rodríguez-Zúñiga, AC, Gómez-Almaguer, D
• Formato: artículo
• Fecha de Publicación: 2022
• Institución: Instituto Nacional de Enfermedades Neoplásicas
• Repositorio: INEN-Institucional
• Lenguaje: inglés
• OAI Identifier: oai:repositorio.inen.sld.pe:20.500.14703/337
• Enlace del recurso: https: //doi.org/10.1080/16078454.2021.2024940; https://hdl.handle.net/20.500.14703/337
• Nivel de acceso: acceso abierto
• Materia: Acute myeloid leukemia; azacytidine; BCL-2 inhibitor; cytarabine; venetoclax; https://purl.org/pe-repo/ocde/ford#3.02.21

Objectives: Venetoclax combinations are a new standard for patients with acute myeloid leukemia (AML). We aimed to evaluate the safety and efficacy of these combinations in a period of accelerated approval in Latin-America. Methods: This observational study evaluated adults with acute myeloid leukemia who received venetoclax-based therapy in 11 public or private centers in Mexico and Peru for both newly diagnosed or relapsed and refractory AML. Results: Fifty patients were included